NeurologyLive

06/06/2026

🗣️ What does Parkinson's speech therapy actually feel like?

Chief Program Officer Anissa Mitchell spoke with NeurologyLive to describe the session where clinicians performed the same speech therapy exercises their patients complete

🎯 The goal: better understand how these therapies improve communication, independence, and quality of life for people living with PD

Make sure to stay tuned to NeurologyLive's website for more ATMRD 2026 coverage! Parkinson & Movement Disorder Alliance

06/06/2026

🧠 NeurologyLive is in Washington, D.C., for Day 2️⃣ of ‼️

Our coverage continues as we bring you the latest movement disorder research, key clinical updates, and expert insights from leaders across the field 👩‍⚕️

Be sure to visit https://hubs.li/Q04kpj_j0 for breaking news, exclusive interviews, and comprehensive conference coverage! Parkinson & Movement Disorder Alliance

06/06/2026

🎤 Day 1️⃣ of concluded with a special keynote featuring Ryan Reynolds

🧠 The Deadpool actor moderated a discussion with Dr. Torres-Yaghi and a couple navigating Parkinson disease (PD), offering perspectives on the impact of PD-related hallucinations and delusions. Reynolds also reflected on his own family's experience with the disease, sharing insights from his father's journey with Parkinson's.

💡 The presentation provided a memorable close to the first day of ATMRD and helped spotlight the importance of education, awareness, and patient-centered care. Stay tuned for more highlights from as NeurologyLive continues its coverage of the congress Parkinson & Movement Disorder Alliance

06/05/2026

At , John Corboy, MD, professor of neurology at the University of Colorado Anschutz School of Medicine, discussed 2 common misconceptions about discontinuing disease-modifying therapies in multiple sclerosis. The Consortium of Multiple Sclerosis Centers

🎙️💬 Interested in seeing more interviews? Head on over to NeurologyLive!

06/05/2026

🎤 "Parkinson's is often studied through a microscope. We'd like to take a wide-angle lens."

👨‍⚕️ In this clip, Robert Cochrane, PhD, met with NeurologyLive to discuss why future Parkinson's disease clinical trials should place greater emphasis on the perspectives of patients and care partners

Be sure to visit NeurologyLive's website for more expert insights and conference coverage from and Parkinson & Movement Disorder Alliance

06/05/2026

🧠✨ At , Kristen Krysko, MD, neurologist, BARLO MS Centre at St. Michael's Hospital, talked about 3 common myths about pregnancy and multiple sclerosis. The Consortium of Multiple Sclerosis Centers Unity Health Toronto

View this conversation and more at NeurologyLive's website! 😉👍

06/05/2026

📣 We're officially underway at ATMRD 2026!

🧠 Today kicks off the first day of presentations, discussions, and research updates focused on movement disorders and neurodegenerative diseases. Throughout the meeting, we'll be sharing expert interviews, important clinical findings, and highlights from sessions covering Parkinson disease, Huntington disease, ataxia, and more.

📌 Be sure to follow NeurologyLive's coverage throughout the conference as we bring you the latest news and insights directly from the meeting.

06/05/2026

🧠✨ At , Rachel Kenney, PhD, assistant professor of neurology and population health at NYU Grossman School of Medicine, discussed the integration of optical coherence tomography into the 2024 McDonald Criteria. The Consortium of Multiple Sclerosis Centers

Check out more of our conference coverage on our site! 👉💻

06/04/2026

🩺 Could changing the language we use improve diagnosis and treatment for patients with spinal cord inflammation?

At CMSC 2026, neurologist Kyle Blackburn, MD, discussed proposed updates to the diagnostic criteria and terminology for myelitis, emphasizing a move away from the broad label "transverse myelitis."

Why it matters:
🧠 New biomarkers and imaging techniques have transformed diagnosis over the past two decades
🔍 Some patients initially labeled with transverse myelitis are later found to have a different inflammatory condition—or a noninflammatory mimic
⚡ Earlier and more accurate diagnosis can lead to more appropriate treatment
📚 Standardized terminology may improve both clinical care and future research

The goal is simple: help clinicians reach the right diagnosis sooner and improve outcomes for patients with inflammatory spinal cord disorders.

📖 Read more: https://hubs.li/Q04jWvvl0

Kyle Blackburn, MD, a neurologist at UT Southwestern Medical Center, discussed new proposed updates to the diagnostic criteria and nosology for myelitis presented at the 2026 CMSC Annual Meeting.

06/04/2026

🧠 Could a new oral therapy help change the course of Huntington disease?

Updated phase 1/2 data on SKY-0515 showed sustained reductions in key disease biomarkers and encouraging clinical trends through 12 months of treatment

Highlights include:
🧬 Up to 69% lowering of mutant huntingtin protein (mHTT)
📉 Up to 26% reduction in PMS1 mRNA
📈 Positive trends across measures of motor, cognitive, and functional outcomes
💊 Oral, once-daily administration
🌎 Global phase 2/3 FALCON-HD study continues enrollment

While additional data are needed to determine whether these biomarker changes translate into long-term clinical benefit, the findings provide further support for SKY-0515's potential as a disease-modifying approach in Huntington disease

📖 Read more: https://hubs.li/Q04jVvjp0

12-montn interim findings from an ongoing phase 1/2 study showed up to 69% reductions in mutant huntingtin protein and favorable cUHDRS trends with the investigational oral RNA-splicing modifier SKY-0515.